Detalhe da pesquisa
1.
Pharmacokinetic and Safety Profile of the Novel HIV Nonnucleoside Reverse Transcriptase Inhibitor MK-8507 in Adults without HIV.
Antimicrob Agents Chemother
; 65(12): e0093521, 2021 11 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-34516246
2.
Pharmacokinetic Interactions between the Hepatitis C Virus Inhibitors Elbasvir and Grazoprevir and HIV Protease Inhibitors Ritonavir, Atazanavir, Lopinavir, and Darunavir in Healthy Volunteers.
Antimicrob Agents Chemother
; 63(4)2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30745392
3.
Assessment of drug interaction potential between the HCV direct-acting antiviral agents elbasvir/grazoprevir and the HIV integrase inhibitors raltegravir and dolutegravir.
J Antimicrob Chemother
; 74(3): 710-717, 2019 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30541077
4.
Pharmacokinetics of elbasvir and grazoprevir in subjects with end-stage renal disease or severe renal impairment.
Eur J Clin Pharmacol
; 75(5): 665-675, 2019 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-30680407
5.
Effect of letermovir on levonorgestrel and ethinyl estradiol pharmacokineticsâ©.
Int J Clin Pharmacol Ther
; 57(9): 450-457, 2019 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-31232280
6.
Effect of Hepatic Impairment on the Pharmacokinetics of Grazoprevir, a Hepatitis C Virus Protease Inhibitor.
Antimicrob Agents Chemother
; 61(12)2017 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-28947470
7.
No clinically meaningful pharmacokinetic interaction between the hepatitis C virus inhibitors elbasvir and grazoprevir and the oral contraceptives ethinyl estradiol and levonorgestrel.
Eur J Clin Pharmacol
; 73(5): 593-600, 2017 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-28233047
8.
Assessment of the Abuse Potential of the Orexin Receptor Antagonist, Suvorexant, Compared With Zolpidem in a Randomized Crossover Study.
J Clin Psychopharmacol
; 36(4): 314-23, 2016 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-27253658
9.
Odanacatib, a selective cathepsin K inhibitor to treat osteoporosis: safety, tolerability, pharmacokinetics and pharmacodynamics--results from single oral dose studies in healthy volunteers.
Br J Clin Pharmacol
; 75(5): 1240-54, 2013 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-23013236
10.
Drug-Drug Interaction of Letermovir and Atorvastatin in Healthy Participants.
Clin Pharmacol Drug Dev
; 11(4): 420-428, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35157785
11.
Estimating time to steady state using the effective rate of drug accumulation.
Pharm Stat
; 10(1): 27-33, 2011.
Artigo
em Inglês
| MEDLINE | ID: mdl-20035533
12.
Assessment of Pharmacokinetic Interaction Between Letermovir and Fluconazole in Healthy Participants.
Clin Pharmacol Drug Dev
; 10(2): 198-206, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32700459
13.
Safety, tolerability, and pharmacokinetics of single- and multiple-dose administration of islatravir (MK-8591) in adults without HIV.
Clin Transl Sci
; 14(5): 1935-1944, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34463432
14.
Evaluation of Pharmacokinetic Drug Interactions of the Direct-Acting Antiviral Agents Elbasvir and Grazoprevir with Pitavastatin, Rosuvastatin, Pravastatin, and Atorvastatin in Healthy Adults.
Clin Drug Investig
; 41(2): 133-147, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-33527237
15.
Atogepant Is Not Associated With Clinically Meaningful Alanine Aminotransferase Elevations in Healthy Adults.
Clin Transl Sci
; 14(2): 599-605, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33142014
16.
Ubrogepant Is Not Associated With Clinically Meaningful Elevations of Alanine Aminotransferase in Healthy Adult Males.
Clin Transl Sci
; 13(3): 462-472, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-31899602
17.
Single-dose pharmacokinetics and pharmacodynamics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects.
Br J Clin Pharmacol
; 68(4): 535-45, 2009 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-19843057
18.
Lack of effect of aprepitant or its prodrug fosaprepitant on QTc intervals in healthy subjects.
Anesth Analg
; 109(2): 418-25, 2009 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-19608812
19.
Effect of CYP3A Inhibition and Induction on the Pharmacokinetics of Suvorexant: Two Phase I, Open-Label, Fixed-Sequence Trials in Healthy Subjects.
Clin Drug Investig
; 39(5): 441-451, 2019 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-30810914
20.
Correction to: Effect of CYP3A Inhibition and Induction on the Pharmacokinetics of Suvorexant: Two Phase I, Open-Label, Fixed-Sequence Trials in Healthy Subjects.
Clin Drug Investig
; 39(5): 453-454, 2019 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-30895461